

BRAIN Biotech AG

Creating a #BiobasedFuture

Capital Markets Day 2023

Zwingenberg, February 27, 2023

WE SUPPORT




Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.



Building the Future in Biotech: Incubator Pipeline Update Adriaan Moelker, CEO

BRAIN Incubator

significant value creation potential



- 🟢 On track
- 🔴 Program on hold or without a partner
- 🟡 Contractual, technology or registration hurdles still need attention
- 🟡 (🟢) Phase 1 has been successfully completed but contract negotiations for the next development phase are progressing but not yet finalized


Progress since CMD 09/21

*1: BRAIN-Group rNPV FCF+TV: **Small** < €5M, **Medium** €5M - €15M, **Large**: €15M+
 *2: **Prod**: Product sales. **Fee**: Research fee income. **MSP**: Milestone payments. **Lic**: License/royalty payments **Tec**: Tech fees **Prof**: Entity formation or profit participation
 *3: **B/A**: BioActives, **E/P**: Enzymes and proteins, **M/O**: Microorganisms/starter cultures
 ND: not disclosed

Salt 1: successful market launch in 2022
 Brazzein shelved for new partners

Fermented Beverages & Ingredients: Creating a Platform Business

innovation box: combining the right substrate & microorganism to create healthier food



Variety of substrates

- Vine leaves
- Fruit juice
- Stevia leaves
- Peas
- Coffee beans
- Carrot pomace
- Brewer's grain
- Potato pulp
- ...

Selection of microorganism(s)

- Agile collection of more than 600 food-related and food-grade microorganisms
- Screening technology
- Microbial strain optimization (classical breeding, GMO)

Fermentation

- Micro(aerobic) & anaerobic
- Submerged

Prototyping


- FoodLab:
- Sensory evaluation
 - Taste optimization
 - Packaging & labelling

Possible end products

- No/low alcohol beverages
- Sweeteners
- Plant-based dairy products
- Enzymes
- Pet food
- Alternative proteins (SCP)
- Decaffeinated coffee

Fermented Beverages & Ingredients

innovation box: customer solutions from proprietary IP



Perillic Active / Fermented Orange Oil – Efficient Natural Antimicrobial

partner model based on proprietary BRAIN technology

B·R·A·I·N

Production @ partner CMO

Key Goals

1. Reducing production costs and investment
2. Outlicensing to new partners

Remaining Challenge

- Cost in use

Existing Partner for distribution & approval for US

Territory: USA, Canada, Mexico

Fields: Food & Beverage, Nutrition, Pet Food

Regulatory: FDA-GRAS

Timeline: Late in 2023

Potential partner for production, distribution & approval for EU & RoW

Territory: Segment of US/Bakery (tbd), EU, RoW

Fields: Food & Beverage (especially Bakery)

Regulatory: EFSA (pre-marketing)


Timeline: +24 month after GRAS

Perillic Active / Fermented Orange Oil – Application Testing in Bread


our product works well in real applications



Dough



Breads




Project Schedule „Urban Mining“

complementary skills and clear path to market

Our immediate plans:

- Reach communication milestone by end of Q1; Partner announcement
- Transfer BioXtractor 2.0 to partner as demo facility for scale-up
- Develop „Franchise Model“ with partner to market proprietary IP



Vessel Upgrade
In progress

SolasCure / Aurase – Phase 2a Clinical Trials Progressing Well

all options evaluated by BRAIN for next stages of clinical development

- ✓ Phase 2a trials in now complete with full readout expected for Q2
- ✓ Preliminary results indicate the continued potential of Aurase as a beneficial treatment option for patients needing debridement

- Program will require additional funding to enter next clinical phase
 - All options evaluated by BRAIN and other SolasCure shareholders
 - BRAIN will divest or dilute

- BRAIN continues to keep additional upside from Aurase production or license/royalty income

Received: 11 November 2022 | Accepted: 22 December 2022

DOI: 10.1111/iwj.14079

ORIGINAL ARTICLE

IWJ WILEY




Preliminary evidence supporting a new enzymatic debridement product for use in chronic wounds

David M. Fairlamb¹ | Bela Kelety^{1,2} | Anke Bachert² |
Anika Scholtissek² | Richard D. Jones³ | Stephen C. Davis⁴ |
Robert S. Kirsner⁴

PHA121 – Innovative Oral Treatment for Hereditary Angioedema (HAE)

clinical development by Pharvaris*

Wholly-owned pipeline focused on bradykinin B2 receptor mechanism



Regulatory Update

- In August 2022, the U.S. Food & Drug Administration (FDA) placed a hold on the clinical trials of PHA121 in the U.S. based on its review of nonclinical data
- The agency requested that Pharvaris conduct an additional long-term rodent toxicology study and update the Investigator’s Brochure
- Pharvaris participated in a Type A meeting with the FDA to discuss paths to address the on-demand and prophylactic holds
- A protocol for a 26-week rodent toxicology study has been finalized with the FDA and the study will initiate soon
- Outside the U.S., the regulatory status remains unchanged for the CHAPTER-1 study and other studies, including long-term extension RAPIDe-2 study

* The FDA has placed a clinical hold on the clinical trials of PHA121 in the U.S.; timeline based on studies ongoing outside the U.S.; see slide 15 for an update on our clinical program

*all data/statements provided by Pharvaris, status January/February 2023, please refer to <https://ir.pharvaris.com>